Integrin Beta 7 Market Size, Scope, Overview, Drivers and Key Vendor Analysis by 2017

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The latest report Integrin Beta 7 Pipeline Review, H2 2017, outlays comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. Interactions involve the tripeptide L-D-T in MADCAM1, and L-D-V in fibronectin. It binds to HIV-1 gp120 that allows the virus to enter GALT (major trigger of AIDS disease).  The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 1 and 2 respectively. Report covers products from therapy areas Gastrointestinal, Infectious Disease, Immunology and Oncology which include indications Ulcerative Colitis, Crohn’s Disease (Regional Enteritis), Human Immunodeficiency Virus (HIV) Infections (AIDS).

Browse Detail Report With TOC @ http://www.hexareports.com/report/integrin-beta-7-gut-homing-receptor-beta-subunit-or-itgb7-pipeline-review-h2-2017

Furthermore, this report also reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
  • The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Request A Sample copy of This Report @ http://www.hexareports.com/report/integrin-beta-7-gut-homing-receptor-beta-subunit-or-itgb7-pipeline-review-h2-2017/request-sample

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics

Reasons To Buy

  1. Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  2. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  3. Identify and understand the targeted therapy areas and indications for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
  4. Identify the use of drugs for target identification and drug repurposing
  5. Identify potential new clients or partners in the target demographic
  6. Develop strategic initiatives by understanding the focus areas of leading companies
  7. Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

For More Details Visit @ Hexa Reports

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s